sb 203580 has been researched along with 2-tert-butylhydroquinone in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (2-tert-butylhydroquinone) | Trials (2-tert-butylhydroquinone) | Recent Studies (post-2010) (2-tert-butylhydroquinone) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 633 | 2 | 300 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fahl, WE; Kong, AN; Lei, W; Mandlekar, S; Tan, TH; Yu, R | 1 |
1 other study(ies) available for sb 203580 and 2-tert-butylhydroquinone
| Article | Year |
|---|---|
p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens.
Topics: Animals; Antioxidants; beta-Naphthoflavone; Butylated Hydroxyanisole; Carcinogens; Enzyme Activation; Enzyme Induction; Gene Expression Regulation, Enzymologic; Genes, Reporter; Humans; Hydroquinones; Imidazoles; Inactivation, Metabolic; Isothiocyanates; Kinetics; MAP Kinase Kinase 3; Mice; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; NAD(P)H Dehydrogenase (Quinone); p38 Mitogen-Activated Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Sulfoxides; Thiocyanates; Tumor Cells, Cultured | 2000 |